nach oben

European Radiology

Erschienen in:

25.08.2016 | Oncology

Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus ⁹⁰Y-radioembolization for hepatocellular carcinoma

verfasst von: Johannes M. Ludwig, Di Zhang, Minzhi Xing, Hyun S. Kim

Erschienen in: European Radiology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 (⁹⁰Y)-radioembolization for hepatocellular carcinoma (HCC).

Methods

Studies comparing conventional (c)TACE versus ⁹⁰Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus ⁹⁰Y-radioembolization was used. Wilcoxon rank-sum test was used to compare baseline characteristics. A priori defined sensitivity analysis of stratified study subgroups was performed for primary outcome analyses. Publication bias was tested by Egger’s and Begg’s tests.

Results

Fourteen studies comparing DEB-TACE or ⁹⁰Y-radioembolization with cTACE were included. Analysis revealed a 1-year overall survival benefit for DEB-TACE over ⁹⁰Y-radioembolization (79 % vs. 54.8 %; OR: 0.57; 95 %CI: 0.355-0.915; p = 0.02; I-squared: 0 %; p > 0.5), but not for the 2-year (61 % vs. 34 %; OR: 0.65; 95%CI: 0.294-1.437; p = 0.29) and 3-year survival (56.4 % vs. 20.9 %; OR: 0.713; 95 % CI: 0.21-2.548; p = 0.62). There was significant heterogeneity in the 2- and 3-year survival analyses. The pooled median overall survival was longer for DEB-TACE (22.6 vs. 14.7 months). There was no significant difference in tumour response rate.

Conclusion

DEB-TACE and ⁹⁰Y-radioembolization are efficacious treatments for patients suffering from HCC; DEB-TACE demonstrated survival benefit at 1-year compared to ⁹⁰Y-radioembolization but direct comparison is warranted for further evaluation.

Key Points

• This meta-analysis shows greater 1-year survival benefit for DEB-TACE over ⁹⁰ Y-radioembolization.

• DEB-TACE has a favourable 2- & 3-year survival benefit trend over ⁹⁰ Y-radioembolization.

• No significant difference for tumour response was detected.

• Direct comparison of these methods for a more robust evaluation is warranted.

Howlader N, Noone A, Krapcho M et al (2013) SEER cancer statistics review, 1975-2011. National Cancer Institute, Bethesda, MD. Available via http://seer.cancer.gov/csr/1975_2011/. Accessed 17 Nov 2014

Ferlay J, Soerjomataram I, Dikshit R et al (2014) Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. doi:10.1002/ijc.29210 PubMed

Khan AS, Fowler KJ, Chapman WC (2014) Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 20:15007–15017CrossRefPubMedPubMedCentral

European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef

Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379:1245–1255CrossRefPubMed

Boulin M, Hillon P, Cercueil JP et al (2014) Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther 39:1301–1313CrossRefPubMed

Abdel-Rahman O, Elsayed ZA (2013) Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 58:3389–3396CrossRefPubMed

Fong ZV, Tanabe KK (2014) The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 120:2824–2838CrossRefPubMed

Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481CrossRefPubMed

10.

Huang K, Zhou Q, Wang R, Cheng D, Ma Y (2013) Doxorubicin-eluting bead versus conventional transarterial chemoembolization for the treatment of HCC: a meta-analysis (Provisional abstract). J Gastroenterol Hepatol

11.

Vente MAD, Wondergem M, van der Tweel I et al (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: A structured meta-analysis. Eur Radiol 19:951–959CrossRefPubMed

12.

Murthy R, Kamat P, Nunez R, Salem R (2008) Radioembolization of yttrium-90 microspheres for hepatic malignancy. Semin Interv Radiol 25:48–57CrossRef

13.

Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS (2013) 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2:435–444CrossRefPubMed

14.

Pitton MB, Kloeckner R, Ruckes C et al (2014) Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. doi:10.1007/s00270-014-1012-0 PubMedPubMedCentral

15.

Seinstra BA, Defreyne L, Lambert B et al (2012) Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials 13:144CrossRefPubMedPubMedCentral

16.

Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRefPubMedPubMedCentral

17.

Recchia F, Passalacqua G, Filauri P et al (2012) Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicineluting beads compared with lipiodol. Oncol Rep 27:1377–1383PubMed

18.

Song MJ, Chun HJ, do Song S et al (2012) Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57:1244–1250CrossRefPubMed

19.

Sacco R, Bargellini I, Bertini M et al (2011) Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22:1545–1552CrossRefPubMed

20.

Ferrer Puchol MD, la Parra C, Esteban E et al (2011) Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Radiologia 53:246–253CrossRefPubMed

21.

Wiggermann P, Sieron D, Brosche C et al (2011) Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit 17:CR189–CR195CrossRefPubMedPubMedCentral

22.

Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 101:476–480PubMed

23.

Kolligs FT, Bilbao JI, Jakobs T et al (2014) Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. doi:10.1111/liv.12750 PubMed

24.

El Fouly A, Ertle J, El Dorry A et al (2015) In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 35:627–635CrossRefPubMed

25.

Moreno-Luna LE, Yang JD, Sanchez W et al (2013) Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 36:714–723CrossRefPubMed

26.

Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507, e492CrossRefPubMed

27.

Lance C, McLennan G, Obuchowski N et al (2011) Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 22:1697–1705CrossRefPubMed

28.

Kooby DA, Egnatashvili V, Srinivasan S et al (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21:224–230CrossRefPubMed

29.

Carr BI, Kondragunta V, Buch SC, Branch RA (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116:1305–1314CrossRefPubMedPubMedCentral

30.

Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13CrossRefPubMedPubMedCentral

31.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

32.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed

33.

Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–691CrossRefPubMed

34.

Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol 14:S199–S202CrossRefPubMed

35.

Salem R, Lewandowski RJ, Gates VL et al (2011) Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 22:265–278

36.

Sangro B, Salem R (2014) Transarterial chemoembolization and radioembolization. Semin Liver Dis 34:435–443CrossRefPubMed

37.

Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52–64CrossRefPubMed

38.

Gorodetski B, Chapiro J, Schernthaner R et al (2016) Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. doi:10.1007/s00330-016-4445-9 PubMed

39.

Salem R, Gilbertsen M, Butt Z et al (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11:1358–1365, e1351CrossRefPubMed

40.

Prajapati HJ, Rafi S, El-Rayes BF, Kauh JS, Kooby DA, Kim HS (2012) Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. J Vasc Interv Radiol 23:1286–1293, e1281CrossRefPubMed

41.

Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472CrossRefPubMedPubMedCentral

42.

Glenny AM, Altman DG, Song F et al (2005) Indirect comparisons of competing interventions. Health Technol Assess 9:1–134, iii-ivCrossRefPubMed

43.

Cornell JE (2014) Random-effects meta-analysis of inconsistent effects. In response. Ann Intern Med 161:380CrossRefPubMed

44.

Chiappelli F, Brant XMC, Neagos N, Oluwadara OO, Ramchandani MH (2010) Evidence-based practice: toward optimizing clinical outcomes. Springer, Berlin HeidelbergCrossRef

Titel: Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma
verfasst von: Johannes M. Ludwig
Di Zhang
Minzhi Xing
Hyun S. Kim
Publikationsdatum: 25.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 5/2017
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-016-4548-3

Neu im Fachgebiet Radiologie

08.04.2024 | Andrologie | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus ⁹⁰Y-radioembolization for hepatocellular carcinoma

Abstract

Objective

Methods

Results

Conclusion

Key Points

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Multicenter external validation of two malignancy risk prediction models in patients undergoing 18F-FDG-PET for solitary pulmonary nodule evaluation

MRI shows thickening and altered diffusion in the median and ulnar nerves in multifocal motor neuropathy

Prognostic aspects of dynamic contrast-enhanced magnetic resonance imaging in synchronous distant metastatic rectal cancer

Volumetric MRI study of the intrauterine growth restriction fetal brain

Usage of structured reporting in radiological practice: results from an Italian online survey

Radiation doses to operators performing transjugular intrahepatic portosystemic shunt using a flat-panel detector-based system and ultrasound guidance for portal vein targeting

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie